Autres langues Cyclo Therapeutics, Inc.

Actions

CYTH

US23254X2018

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/05/2024			Varia. 5j.	Varia. 1 janv.
1,42 ^USD	+1,43%		+1,43%	-10,69%

01/05	CYCLO THERAPEUTICS, INC. : HC Wainwright favorable sur le dossier	ZM
18/03	Cyclo Therapeutics, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	16/05
Cyclo Therapeutics : Corporate Presentation	02/05
Cyclo Therapeutics : Corporate Presentation	18/04
Cyclo Therapeutics : Corporate Presentation	18/03
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	18/03
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease	15/03
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	14/03
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease	14/03
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office	30/01
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office	29/01
Cyclo Therapeutics : Modification to Rights of Security Holders - Form 8-K	28/12
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	27/12
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.	27/12
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors	27/12
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	27/12
Cyclo Therapeutics : Scientific Presentation	20/12
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1	18/12
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1	18/12
Cyclo Therapeutics : Material Event - Form 8-K	18/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cyclo Therapeutics, Inc.

Actions

CYTH

US23254X2018

Autres langues

Filtres